Latest Ratios: P/E Ratio 40.1x · EV/EBITDA 23.8x · ROE 26.8%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.0B | $1.9B | $1.3B | — | — | — | — | — | — |
| Enterprise Value | $2.9B | $1.9B | $1.3B | — | — | — | — | — | — |
| P/E Ratio → | 40.13 | 38.58 | — | — | — | — | — | — | — |
| P/S Ratio | 2.04 | 1.31 | 1.02 | — | — | — | — | — | — |
| P/B Ratio | 13.63 | 8.74 | 8.38 | — | — | — | — | — | — |
| P/FCF | 30.91 | 23.60 | 30.20 | — | — | — | — | — | — |
| P/OCF | 29.64 | 18.99 | 21.67 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.30 | 1.04 | — | — | — | — | — | — |
| EV / EBITDA | 23.85 | 16.86 | — | — | — | — | — | — | — |
| EV / EBIT | 33.11 | 25.32 | — | — | — | — | — | — | — |
| EV / FCF | — | 23.25 | 30.82 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 19.5% | 19.5% | 19.9% | 19.9% | 20.4% | 20.4% | 20.0% | 20.5% | 20.5% |
| Operating Margin | 6.1% | 6.1% | -5.1% | 3.9% | 5.7% | 3.8% | 4.4% | 4.9% | 4.3% |
| Net Profit Margin | 3.4% | 3.4% | -7.1% | 2.3% | 3.9% | 2.1% | 2.7% | 3.1% | 2.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 26.8% | 26.8% | -83.2% | 35.2% | 54.8% | 27.1% | 42.1% | 45.4% | 21.6% |
| ROA | 13.4% | 13.4% | -29.5% | 9.1% | 14.4% | 7.2% | 9.6% | 11.5% | 8.1% |
| ROIC | 36.6% | 36.6% | -31.1% | 23.0% | 33.7% | 21.3% | 23.6% | 26.4% | — |
| ROCE | 41.5% | 41.5% | -40.6% | 29.5% | 38.7% | 23.6% | 27.0% | 30.6% | 22.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.20 | 1.16 | 0.83 | 1.03 | 0.88 | 2.06 | 0.64 |
| Debt / EBITDA | 0.33 | 0.33 | — | 1.17 | 0.92 | 1.18 | 1.19 | 1.14 | 1.12 |
| Net Debt / Equity | — | -0.13 | 0.17 | 1.14 | 0.82 | 0.75 | 0.78 | 2.05 | 0.61 |
| Net Debt / EBITDA | -0.26 | -0.26 | — | 1.16 | 0.91 | 0.86 | 1.06 | 1.14 | 1.06 |
| Debt / FCF | — | -0.35 | 0.61 | 1.22 | 1.96 | 0.81 | 1.18 | 1.37 | 1.23 |
| Interest Coverage | 111.41 | 111.41 | -19.28 | 14.19 | 26.78 | 18.30 | 14.76 | 14.94 | 13.25 |
Net cash position: cash ($66M) exceeds total debt ($37M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.38 | 1.38 | 1.05 | 0.94 | 1.07 | 1.00 | 1.09 | 1.00 | 1.24 |
| Quick Ratio | 1.11 | 1.11 | 0.77 | 0.67 | 0.70 | 0.71 | 0.72 | 0.66 | 0.82 |
| Cash Ratio | 0.41 | 0.41 | 0.03 | 0.01 | 0.01 | 0.13 | 0.07 | 0.00 | 0.03 |
| Asset Turnover | — | 3.51 | 3.83 | 3.86 | 3.55 | 3.36 | 3.38 | 3.55 | 3.30 |
| Inventory Turnover | 26.91 | 26.91 | 24.27 | 22.81 | 17.45 | 19.06 | 18.45 | 17.93 | 17.33 |
| Days Sales Outstanding | — | 25.60 | 28.87 | 26.96 | 27.24 | 25.46 | 22.70 | 28.34 | 28.97 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 2.8% | — | — | — | — | — | — |
| Payout Ratio | — | — | — | 160.7% | 87.0% | 106.4% | 54.2% | 114.6% | 156.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.5% | 2.6% | — | — | — | — | — | — | — |
| FCF Yield | 3.2% | 4.2% | 3.3% | — | — | — | — | — | — |
| Buyback Yield | 1.0% | 1.5% | 4.4% | — | — | — | — | — | — |
| Total Shareholder Yield | 1.0% | 1.5% | 7.2% | — | — | — | — | — | — |
| Shares Outstanding | — | $63M | $62M | $61M | $61M | $61M | $61M | $61M | $61M |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GRDN stock.
Guardian Pharmacy Services, Inc.'s current P/E ratio is 40.1x. The historical average is 38.6x. This places it at the 100th percentile of its historical range.
Guardian Pharmacy Services, Inc.'s current EV/EBITDA is 23.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 16.9x.
Guardian Pharmacy Services, Inc.'s return on equity (ROE) is 26.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 21.2%.
Based on historical data, Guardian Pharmacy Services, Inc. is trading at a P/E of 40.1x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Guardian Pharmacy Services, Inc. has 19.5% gross margin and 6.1% operating margin.
Guardian Pharmacy Services, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Thin margins under reimbursement pressure
Metrics are mathematically derived from official filings.
Premium Multiples Demand Sustained Growth
Based on reported figures, GRDN trades at 42.3x trailing earnings and 25.2x EV/EBITDA, a premium that assumes growth durability even as year-over-year revenue growth decelerated to negative territory in the latest quarter.
The 42.3x trailing P/E and 2.25 PEG ratio indicate the market is pricing in earnings growth well above what the most recent quarter supports, since the Q3 2026 EPS miss against a $0.41 estimate weakens the near-term earnings base. Compared with the diversified distributor peers referenced in the peer set, the multiple is elevated, which suggests investors are paying a complexity premium for the long-term care service model rather than a pure distribution valuation. Investors should monitor whether forward EV/EBITDA compression toward 22.4x reflects genuine earnings recovery or simply a lower price base.
Thin Margins Limit Earnings Cushion
According to reported quarterly figures, GRDN's gross margin held near 23.0% in Q3 2026 while operating margin of 6.8% and net margin of 5.0% leave a narrow buffer against reimbursement cuts.
Gross margin has stayed in a narrow 19.4% to 23.0% band over the ten quarters shown, which suggests pricing power is limited and the business remains tethered to drug distribution economics. The gap between the 6.8% operating margin and 5.0% net margin, combined with 26.8% ROE, implies that returns are being generated more by balance sheet structure than by unusually strong operating profitability. Operating margin volatility between 3.7% and 9.2% suggests operating leverage is uneven and warrants monitoring of SG&A discipline as revenue scales.
Equity Returns Diverge From Invested Capital
As reported in financial statements, GRDN's ROIC of 9.4% in Q3 2026 sits well below its 26.8% ROE, pointing to returns that are heavily amplified by a thin equity base relative to operating earnings.
The spread between ROE and ROIC is a signal that much of the reported equity return reflects financial structure rather than deep capital efficiency, since the company carries minimal debt yet still shows modest invested-capital returns. ROIC has trended in a 5% to 14% range across recent quarters, which suggests compounding is real but inconsistent. Investors should track whether ROIC expands as goodwill from acquisitions, which rose from $66.4M to $82.0M, is absorbed into earnings.
Cash Build Strengthens Near-Term Coverage
Based on GRDN's reported balance sheet, the current ratio improved from 1.05 to 1.65 and quick ratio reached 1.33, indicating a materially larger liquidity buffer than in late 2024.
The improvement in quick ratio to 1.33 suggests the company can meet short-term obligations without relying on inventory liquidation, which is meaningful for a pharmacy distributor holding dispensing stock. However, the cash build coincides with thin earnings margins, so the liquidity position may be more dependent on working capital timing than on sustained profit generation. Under severe stress, the position would likely depend on whether receivables collect on schedule given DSO near 26 days.
Misapplied Metric Obscures Working Capital Reality
The debt-to-equity ratio is most commonly misapplied to GRDN, as its 0.13 reading may understate financial risk when cash conversion swings sharply quarter to quarter.
Low D/E is often read as a clean signal of balance sheet safety, but for a business whose operating cash flow relative to net income swung from 0.46x to 2.87x, the more informative measure is cash conversion and working capital intensity. Substituting a free cash flow margin trend or CCC analysis alongside D/E would better reflect the operating reality. Investors should weigh the Q1 2026 working capital outflow as a reminder that a low-leverage ratio does not guarantee stable cash generation.